Insulet Rolls Out Omnipod 5 With Enhanced Algorithm, Abbott Libre 3 Plus Compatibility

MT Newswires Live06-03 20:35

Insulet (PODD) said Wednesday that it has begun rolling out algorithm enhancements for its Omnipod 5 Automated Insulin Delivery system following clearance from the US Food and Drug Administration.

The company said Omnipod 5 is now compatible with Abbott's (ABT) Libre 3 Plus sensor in the US, providing users with additional continuous glucose monitoring options and allowing caregiver monitoring through the LibreLinkUp app.

The update introduces a new 100 mg/dL Target Glucose setting and helps keep users in Automated Mode with fewer interruptions even during prolonged high-glucose events, the company said.

The enhancements will be delivered via over-the-air software updates as compatible Pods become available through US retail channels, Insulet added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment